Lack of response of elephantiasic pretibial myxoedema to treatment with high‐dose intravenous immunoglobulins

[1]  G. Pond,et al.  Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  T. Smith,et al.  Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Hommel,et al.  Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy , 1996, Clinical and experimental immunology.

[4]  S. -. Wu,et al.  TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor. , 1994, Clinical immunology and immunopathology.

[5]  A. Antonelli,et al.  Pretibial myxedema and high-dose intravenous immunoglobulin treatment. , 1994, Thyroid : official journal of the American Thyroid Association.

[6]  W. Heymann.  Cutaneous manifestations of thyroid disease. , 1992, Journal of the American Academy of Dermatology.